Biosimilars: Considerations for Payers.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.American journal of clinical dermatology · 2022
   Trial
2. Early real-world utilization of ADA-adaz (Hyrimoz) in the United States: A retrospective claims-based descriptive study.Medicine · 2026
   Article
3. Bridging approaches to facilitate innovation: building an approach for heated tobacco products from case studies in the food and drug domains a comparative review.Archives of toxicology · 2025
   Review
4. Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024
   Article
5. An international comparative analysis and roadmap to sustainable biosimilar markets.Frontiers in pharmacology · 2023
   Article
6. Biosimilars in Oncology: Latest Trends and Regulatory Status.Pharmaceutics · 2022
   Review
7. Characterizing experiences of non-medical switching to trastuzumab biosimilars using data from internet-based surveys with US-based oncologists and breast cancer patients.Breast cancer research and treatment · 2022
   Article
8. Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into Practice.Journal of the advanced practitioner in oncology · 2022
   Review
9. Public Health Impact of Using Biosimilars, Is Automated Follow up Relevant?International journal of environmental research and public health · 2020
   Review
10. Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2020
    Article
11. Patent Cliffs in the Era of Complex Therapies and Biologics.Pharmaceutical medicine · 2020
    Article
12. Update on Biosimilar Insulins: A US Perspective.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020
    Review
13. Dose equivalency and efficacy of biosimilar erythropoietin stimulating agents: Data from real clinical practice.Pharmacology research & perspectives · 2020
    Article
14. Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb.Journal of managed care & specialty pharmacy · 2020
    Article
15. Current and future roles of biosimilars in oncology practice.Oncology letters · 2020
    Review
16. Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?Frontiers in pharmacology · 2020
    Article
17. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.Targeted oncology · 2019
    Review
18. Biosimilars of low molecular weight heparins: Relevant background information for your drug formulary.British journal of clinical pharmacology · 2019
    Review
19. The Clinical Implications of Nocebo Effects for Biosimilar Therapy.Frontiers in pharmacology · 2019
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as